What is the recommended dosing, monitoring, and contraindications for using propranolol to treat essential tremor in adults?

Propranolol for Essential Tremor in Adults

Start propranolol at 40 mg twice daily (80 mg/day total) and titrate up to 120-240 mg/day in divided doses, as this is the established first-line treatment for essential tremor with the strongest evidence for efficacy. 12

Recommended Dosing

Initial Dosing

• Starting dose: 40 mg twice daily (80 mg/day total)
• Titration: Increase by 40-80 mg every 3-7 days based on response and tolerability
• Target maintenance dose: 120-240 mg/day in 2-3 divided doses 34

Optimal Dosing Range

• Maximum tremor suppression typically occurs at 160-320 mg/day 4
• Doses above 320 mg/day rarely provide additional benefit and increase side effects 4
• Most patients achieve optimal response at relatively low plasma levels, corresponding to daily doses of 120-240 mg 3
• The dose-response relationship varies greatly between individuals—some patients achieve complete suppression at 80 mg/day while others show no response even at 800 mg/day 4

Extended-Release Formulation

If using extended-release capsules 5:

• Start at 80 mg once daily
• Increase to 120-160 mg once daily as needed
• Maximum studied dose: 320 mg once daily
• Note: Extended-release is NOT a simple mg-for-mg substitute for immediate-release tablets; retitration may be necessary

Contraindications (Absolute)

The following are absolute contraindications 5:

• Cardiogenic shock
• Sinus bradycardia and greater than first-degree heart block
• Bronchial asthma
• Known hypersensitivity to propranolol

Relative Contraindications

Use with extreme caution or avoid in:

• Chronic obstructive pulmonary disease (COPD)
• Decompensated heart failure
• Peripheral vascular disease
• Diabetes mellitus (may mask hypoglycemia symptoms)

Pretreatment Evaluation

Before initiating propranolol, perform:

1. Cardiovascular assessment:

   • Heart rate and blood pressure measurement
   • Cardiac auscultation for murmurs or arrhythmias
   • Peripheral pulse examination

2. Respiratory examination:

   • Rule out asthma or significant reactive airway disease
   • Assess for COPD

3. ECG if:

   • Abnormal heart rate
   • History of syncope or arrhythmia
   • Family history of sudden cardiac death
   • Heart murmur detected on examination

4. No routine laboratory testing required for uncomplicated patients

Monitoring During Treatment

Routine Monitoring

• Blood pressure and heart rate at each clinic visit
• Functional tremor assessment using standardized scales (e.g., Fahn-Tolosa-Marin Tremor Rating Scale)
• Follow-up intervals: Every 2-3 months once stable dose achieved

Between Appointments

• No routine BP/HR monitoring needed if patient is well and asymptomatic
• Patients should report: dizziness, excessive fatigue, shortness of breath, or worsening tremor

Expected Efficacy

• Approximately 50-70% of patients respond to propranolol 61
• Improvement is most pronounced in upper extremity action tremor 7
• Poor efficacy for:
  • Head tremor (limited evidence of benefit)
  • Voice tremor
  • Lower extremity tremor
• Response typically seen within days to weeks of achieving therapeutic dose 3

Common Pitfalls and Management

Side Effects

Most common adverse effects:

• Fatigue and lethargy
• Bradycardia and hypotension
• Cold extremities
• Sleep disturbances/vivid dreams
• Sexual dysfunction

Management approach:

• If intolerable side effects occur, consider switching to atenolol or metoprolol (cardioselective beta-blockers) 6
• Reduce dose if bradycardia (HR <50-55 bpm) or symptomatic hypotension develops
• Take with food to minimize gastrointestinal upset

Non-Responders

If inadequate response after 3-month trial at 120 mg/day 8:

• Increase dose to 240-320 mg/day
• If still inadequate, consider adding primidone (combination therapy) 6
• Alternative second-line agents: gabapentin, topiramate 1
• Consider surgical options (deep brain stimulation or thalamotomy) for medication-refractory disabling tremor 2

Discontinuation

• Can be stopped abruptly in most cases, though gradual taper over several weeks is reasonable to avoid potential rebound hypertension or tachycardia
• Gradual withdrawal advisable in patients with coronary artery disease

Key Clinical Pearls

• Propranolol has Level A evidence (established as effective) for limb tremor reduction 12
• Serum propranolol levels do not correlate with tremor suppression—dose based on clinical response, not drug levels 43
• Response tends to deteriorate over time if initial response is less than excellent 8
• Younger patients (<55 years) and those with shorter tremor duration (<12 years) tend to have better long-term responses 8
• For situational/performance tremor only: use propranolol 20-40 mg as needed 30-60 minutes before stressful events 6